← Back

CVRx Inc

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Price · split & dividend adjusted
News & notes moving CVRX
CVRX▼3

CVRx cuts full-year revenue outlook as sales force productivity lags

CVRx reported second-quarter 2026 revenue of $15.7 million, a 16% increase from the prior year, but lowered its full-year revenue guidance to between $58.0 million and $60.0 million. U.S. revenue rose 21% to $14.8 million, driven by growth in heart failure implants and expansion to 258 active implanting centers, while European revenue fell 31% to $0.9 million. The company cited fewer sales territories than anticipated, lower sales force productivity, and a prolonged challenge with one of its largest payers as reasons for the reduced outlook. Gross margin improved to 87%, and net loss narrowed to $14.0 million, or $0.53 per share. Humana issued a Medicare Advantage coverage policy for Barostim therapy effective May 1, 2026, marking the first coverage policy of its kind for the device.
CVRX ▼HUM ▲
GlobeNewswire·20dRead more ▾
CVRX▲

CVRx shares surge 11.6% on strong Q1 results

CVRx shares rallied 11.6% in the last trading session to close at $5.86, driven by higher-than-usual trading volume. The jump came after the medical device company reported first-quarter 2026 results that beat expectations, with a loss per share of 50 cents and revenue of $14.8 million, both surpassing Zacks Consensus Estimates. For the upcoming quarter, analysts expect a loss of 52 cents per share and revenue of $15.64 million, representing a 15.1% year-over-year increase. Despite the strong price move, the consensus EPS estimate for the next quarter has remained unchanged over the last 30 days, and the stock currently carries a Zacks Rank of 3, or Hold.
CVRX ▲
Zacks Investment Research·58dRead more ▾
© 2026 MarketDXAsset